> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Acella Pharma Recalls Subpotent Thyroid Drug
- URL: https://www.fdaweb.com/acella-pharma-recalls-subpotent-thyroid-drug/
- Published: 2021-05-03T12:00:00.000Z
- Updated: 2026-09-14T16:57:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149234

Acella Pharmaceuticals has recalled certain lots of its NP Thyroid (levothyroxine and liothyronine) in 9.5mcg/2.25mcg, 19mcg/4.5mcg, 38mcg/9mcg, 57mcg/13.5mcg, and 75mcg/18mcg tablets because routine testing has found them to be subpotent. The product contains less than 90% of the labeled amount of liothyronine and levothyroxine, according to a [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/acella-pharmaceuticals-llc-issues-voluntary-nationwide-recall-certain-lots-np-thyroidr-thyroid-0?ref=fdaweb.com). Patients who receive sub potent NP Thyroid may experience signs and symptoms of hypothyroidism (underactive thyroid), which may include, fatigue, increased sensitivity to cold, constipation, dry skin, puffy face, hair loss, slow heart rate, depression, swelling of the thyroid gland or unexplained weight gain or difficulty losing weight, the notice says.